Epigenomics AG Adds Regulatory Affairs And Marketing Expertise To Senior Management

Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, announced today the addition of Dr. Michael Wandell as Senior Vice President for Clinical, Regulatory & Quality, and James Douglas as Senior Vice President Marketing & Sales to its senior management team. These appointments position the company to fully realize its own tissue-based molecular pathology product development. For the foreseeable future, the company considers the building of a senior management team for an integrated product company complete. Both Dr. Wandell and Mr. Douglas will be based in Seattle. Epigenomics also sees these additions as a clear statement to leverage its Seattle base to deliver its products to the US market, though it will continue to base the main part of its research and development organization in Berlin and eventually market its products worldwide.

MORE ON THIS TOPIC